136 related articles for article (PubMed ID: 2802041)
1. Immune restoration with interleukin-2 in patients with squamous cell carcinoma of the head and neck.
Wanebo HJ; Jones T; Pace R; Cantrell R; Levine P
Am J Surg; 1989 Oct; 158(4):356-60. PubMed ID: 2802041
[TBL] [Abstract][Full Text] [Related]
2. Contribution of serum inhibitory factors and immune cellular defects to the depressed cell-mediated immunity in patients with head and neck cancer.
Wanebo HJ; Blackinton D; Kouttab N; Mehta S
Am J Surg; 1993 Oct; 166(4):389-94. PubMed ID: 8214299
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-10 as a possible mediator of immunosuppressive effect in patients with squamous cell carcinoma of the head and neck.
Avradopoulos K; Mehta S; Blackinton D; Wanebo HJ
Ann Surg Oncol; 1997 Mar; 4(2):184-90. PubMed ID: 9084857
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of lymphocyte function by head and neck carcinoma cell line soluble factors.
Bailet JW; Lichtenstein A; Chen G; Mickel RA
Arch Otolaryngol Head Neck Surg; 1997 Aug; 123(8):855-62. PubMed ID: 9260552
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 production in head and neck cancer patients.
Hargett S; Wanebo HJ; Pace R; Katz D; Sando J; Cantrell R
Am J Surg; 1985 Oct; 150(4):456-60. PubMed ID: 3876783
[TBL] [Abstract][Full Text] [Related]
6. Head and neck squamous cell carcinoma cell line-induced suppression of in vitro lymphocyte proliferative responses.
Lapointe H; Lampe H; Banerjee D
Otolaryngol Head Neck Surg; 1992 Feb; 106(2):149-58. PubMed ID: 1738546
[TBL] [Abstract][Full Text] [Related]
7. Interleukins 2 and 12 activate natural killer cytolytic responses of peripheral blood mononuclear cells from patients with head and neck squamous cell carcinoma.
Rashleigh SP; Kusher DI; Endicott JN; Rossi AR; Djeu JY
Arch Otolaryngol Head Neck Surg; 1996 May; 122(5):541-7. PubMed ID: 8615973
[TBL] [Abstract][Full Text] [Related]
8. Beta endorphin enhances in vitro lymphokine production in patients with squamous carcinoma of the head and neck.
Wolf GT; Peterson KA
Otolaryngol Head Neck Surg; 1986 Feb; 94(2):224-9. PubMed ID: 2938055
[TBL] [Abstract][Full Text] [Related]
9. [Study of head and neck cancer treatment by administration of autologous cytotoxic lymphocyte induced by stimulation with tumor cell--induction of killer cells by stimulation with allogeneic tumor cell].
Ikawa T; Ishikawa T; Eura M
Nihon Jibiinkoka Gakkai Kaiho; 1988 Dec; 91(12):2079-81. PubMed ID: 3266242
[No Abstract] [Full Text] [Related]
10. Combination nonviral interleukin 2 and interleukin 12 gene therapy for head and neck squamous cell carcinoma.
Li D; Shugert E; Guo M; Bishop JS; O'Malley BW
Arch Otolaryngol Head Neck Surg; 2001 Nov; 127(11):1319-24. PubMed ID: 11701067
[TBL] [Abstract][Full Text] [Related]
11. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
12. In vitro immune modulation by thymosin alpha 1 in patients with head and neck squamous cell carcinoma.
Wolf GT; Peterson KA; Lovett EJ
Head Neck Surg; 1985; 7(5):350-6. PubMed ID: 3879957
[TBL] [Abstract][Full Text] [Related]
13. Immune complexes, serum proteins, cell-mediated immunity, and immune regulation in patients with squamous cell carcinoma of the head and neck.
Veltri RW; Rodman SM; Maxim PE; Baseler MW; Sprinkle PM
Cancer; 1986 Jun; 57(12):2295-308. PubMed ID: 3084060
[TBL] [Abstract][Full Text] [Related]
14. Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients.
Wanebo HJ; Pace R; Hargett S; Katz D; Sando J
Cancer; 1986 Feb; 57(3):656-62. PubMed ID: 3484660
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of interleukin-2 on natural killer activity in lung cancer patients.
Ito M; Suzuki H; Yamashita N; Sugiyama E; Maruyama M; Sato M; Iwata M; Yano S
Anticancer Res; 1984; 4(6):375-8. PubMed ID: 6097158
[TBL] [Abstract][Full Text] [Related]
16. Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma.
Melioli G; Margarino G; Scala M; Mereu P; Bertoglio S; Schenone G; Barbaresi M; Machí AM; Santi L; Badellino F
Laryngoscope; 1992 May; 102(5):572-8. PubMed ID: 1533435
[TBL] [Abstract][Full Text] [Related]
17. Total lymphocyte and T lymphocyte subpopulation levels in head and neck squamous cell carcinomas.
Soysal V; Yigitbasi OG; Alper M; Patiroglu T; Güney E
J Exp Clin Cancer Res; 1998 Jun; 17(2):207-12. PubMed ID: 9700582
[TBL] [Abstract][Full Text] [Related]
18. Depressed PMNC blastogenic response in patients with cancer of the head and neck: a study of IL-2 production, IL-2 consumption, and IL-2 receptor expression.
Eskinazi DP; Perna JJ; Ershow AG; Mihail RC
Laryngoscope; 1989 Feb; 99(2):151-7. PubMed ID: 2783615
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of the lymphokine-activated killer cell response in head and neck cancer patients by combination interleukin-2 and interferon-alpha.
Wanebo H; Blackinton D; Weigel T; Turk P; Mehta S
Am J Surg; 1991 Oct; 162(4):384-7. PubMed ID: 1951894
[TBL] [Abstract][Full Text] [Related]
20. Nonspecific immunity and head and neck cancer: blastogenesis reviewed and revisited.
Eskinazi DP; Helman J; Ershow AG; Perna JJ; Mihail R
Oral Surg Oral Med Oral Pathol; 1985 Dec; 60(6):642-7. PubMed ID: 3865136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
